Handelsavisen
prelaunch
Companies Healthcare 6637.TWO
66
6637.TWO TPEx Advanced Medical Equipment & Technology

6637.Two

$65,80
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
5,02 %
Op margin
19,2 %
ROE
16,6 %
Net margin
15,9 %
Debt / equity
0,41
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

6637.TWO is a healthcare equipment company that designs, develops, and sells advanced medical devices and technologies, primarily generating revenue through product sales and service contracts.

Business. 6637.TWO is a healthcare equipment company that designs, develops, and sells advanced medical devices and technologies, primarily generating revenue through product sales and service contracts.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
ActivityHealthcare Equipment
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
16,6 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 6637.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 6637.TWO. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    6637.TWO is a healthcare equipment company that designs, develops, and sells advanced medical devices and technologies, primarily generating revenue through product sales and service contracts.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryAdvanced Medical Equipment & Technology
    ActivityHealthcare Equipment
    AI synthesis
    GENERATED

    6637.TWO maintains a relatively strong liquidity position, with a current ratio of 3.04, indicating that it has sufficient current assets to cover its current liabilities. However, the company's operating cash flow is negative at -294,387,000 TWD, which contrasts with a positive free cash flow of 113,571,000 TWD, suggesting that capital expenditures are being funded internally. The company's liquidity is assessed as medium, with a debt-to-equity ratio of 0.41, indicating a moderate level of leverage.

    In terms of profitability, 6637.TWO reports a return on equity (ROE) of 16.56% and a return on assets (ROA) of 9.69%, both of which are strong indicators of efficient capital use and asset management. These figures suggest that the company is generating solid returns relative to its equity and total assets, which is favorable compared to the industry's typical performance metrics.

    The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher risks if demand in its primary market fluctuates or if regulatory changes impact its operations.

    Looking ahead, the company's growth trajectory is expected to remain stable, with no significant changes in revenue or operating performance anticipated in the next fiscal year. The company's capital expenditures are relatively low at -27,667,000 TWD, indicating a conservative approach to reinvestment. This suggests that the company is not aggressively expanding its operations, which may limit its growth potential in the long term.

    The risk assessment for 6637.TWO indicates a low potential for dilution, with no significant dilution events reported in the recent financial data. However, the company's net cash position is negative after subtracting total debt, which could pose a liquidity risk if cash flow from operations does not improve. The company's debt-to-equity ratio of 0.41 is relatively low, but the negative operating cash flow raises concerns about its ability to service debt obligations.

    Recent financial filings and transcripts do not indicate any major events or strategic shifts that would significantly impact the company's operations or financial performance. The company appears to be maintaining a steady course, with no major announcements or changes in leadership reported in the available data.

    Key takeaways
    • 6637.TWO has a strong return on equity (16.56%) and return on assets (9.69%), indicating efficient use of capital and assets.
    • The company's liquidity is moderate, with a current ratio of 3.04, but its operating cash flow is negative, which could affect its ability to fund operations.
    • The company's debt-to-equity ratio is 0.41, suggesting a relatively low level of leverage, but its net cash position is negative after subtracting total debt.
    • 6637.TWO's revenue is concentrated in a single business segment, which may increase its exposure to market and regulatory risks.
    • The company's capital expenditures are low, indicating a conservative approach to reinvestment and expansion.
    • There are no significant dilution risks reported, but the company's negative operating cash flow raises concerns about its liquidity.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $65,80
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $1.12B
    Net cash
    -$89.7M
    Current ratio
    3.0
    Debt / equity
    0.4
    ROA
    9.7%
    ROE
    16.6%
    Cash conversion
    -159.0%
    CapEx / revenue
    -2.4%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin19,2 %Above P75
    Net Margin15,9 %Above P75
    ROE16,6 %Above P75
    Capex / Rev-2,4 %Above median
    D/E0,41Below median
    Cash Conv-1,59Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • 6637.TWO Market data — financials · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    6637.TWOCanonical
    TPEx · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage